Enveric Biosciences

11/14/2025

Enveric has announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update. See it here: https://bit.ly/47WCCLT

11/12/2025

Enveric is developing its novel neuroplastogen, EB-003, to overcome the limitations of current psychedelic-based treatments. EB-003 has the potential to promote neuroplasticity without hallucinations, making treatment more scalable, accessible, and clinically practical. Learn more about our novel drug: https://bit.ly/3pbHq9W

11/03/2025

According to recent studies, many neuropsychiatric disorders are increasingly linked to impaired brain connectivity. Enveric’s lead molecule, EB-003, has the potential to promote neuroplasticity without hallucinations to address mental health disorders including PTSD, depression and anxiety. For more info, visit: https://bit.ly/3pbHq9W

10/23/2025

Enveric Biosciences Announces Reverse Stock Split https://bit.ly/49j74C7

10/20/2025

Enveric is advancing toward the submission of its IND application for EB-003 which is expected in early 2026. Learn how Enveric is preparing for its IND from our CEO, Joseph Tucker's, recent conversation with Clinical Leader here: https://bit.ly/4n2focN

10/17/2025

A new article from Microdose highlights Enveric's hiring of Fish & Richardson P.C. to contest a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against the Company's issued '276 patent, which appears relevant to the Bretisilocin molecule. Read it here: https://bit.ly/47a1gIj

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being tested, as Gilgamesh Pharmaceuticals moves to challenge Enveric’s patent claims, just weeks ...

10/16/2025

Our CEO, Joseph Tucker, Ph.D., comments on the Company's 23rd issued U.S. patent for novel neuroplastogen molecules. For more info, visit: https://bit.ly/4qbyVKw

10/16/2025

Enveric today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental health disorders. The patent covers a unique series of compounds, which are designed to target key serotonin receptors and drive neuroplasticity. more info: https://bit.ly/4qbyVKw

10/16/2025

"Enveric will vigorously defend its intellectual property and take all steps necessary to maximize the value of its intellectual property for shareholders,” Dr. Joseph Tucker, comments on the company's hiring of Fish and Richardson P.C. to defend its '276 patent. Read more: https://bit.ly/3KJc8pk

10/15/2025

Enveric’s lead product candidate, EB-003, is protected by a different patent family, which is separate and distinct from the patent that appears relevant to Bretisilocin, the molecule recently acquired by AbbVie in a $1.2 billion deal. For more info, visit: https://bit.ly/3KJc8pk

10/15/2025

Enveric Biosciences has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review petition, filed by Gilgamesh Pharmaceuticals, against Enveric’s issued ’276 U.S. Patent which includes claims that appear relevant to the Bretisilocin molecule currently in clinical trials, which AbbVie recently acquired in a deal valued at up to $1.2 billion. Learn more here: https://bit.ly/3KJc8pk

10/14/2025

Enveric Biosciences' Board of Directors has authorized the Company’s Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury strategy opportunities as part of an initiative to enhance shareholder value and support the Company’s long-term growth. The Company remains fully committed to advancing its core biotechnology programs. For more info, visit: https://bit.ly/4q59J8B